Patent: 10,487,098

Summary for Patent: 10,487,098

Title:	Soluble C5aR antagonists
Abstract:	Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): ##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s):	Fan; Pingchen (Fremont, CA), Krasinski; Antoni (Sunnyvale, CA), Mali; Venkat Reddy (Cupertino, CA), Miao; Shichang (Foster City, CA), Punna; Sreenivas (Sunnyvale, CA), Song; Yang (Foster City, CA), Stella; Valentino J. (Lawrence, KS), Zeng; Yibin (Foster City, CA), Zhang; Penglie (Foster City, CA)
Assignee:	ChemoCentryx, Inc. (Mountain View, CA)
Application Number:	16/357,889
Patent Claims:	see list of patent claims

United States Patent 10,487,098 C5a binding inhibition Formula I method-of-use claim analysis and US patent landscape

Executive summary

US Patent 10,487,098 claims a broad method for inhibiting C5a binding in humans using a “Formula I” compound (and pharmaceutical compositions thereof) for a wide set of inflammatory, autoimmune, oncologic, cardiovascular, and cerebrovascular disorders. The independent claim is structured as: (i) C5a-binding inhibition, (ii) broad disease list, (iii) administration of Formula I (or salts) with extensive Markush-style substituent definitions for the chemical scaffold, and (iv) further method breadth via dependent claims that allow combination therapy with a large catalog of immunomodulators, biologics, small molecules, and supportive agents.

The claim set is primarily a chemical-substructure method-of-use claim with very high functional breadth (C5a binding inhibition) and very high legal breadth (large disease taxonomy plus extensive substituent ranges plus open-ended combination therapy). This structure typically creates: (1) strong coverage against direct use of the specific scaffold as a C5a-binding inhibitor, but (2) elevated risks in enforceability where the accused product does not fall within the Markush limits or where prosecution history limits the interpretation of “Formula I,” the definition of the substituent variables, or the functional “inhibiting C5a binding” limitation.

What follows is a claim-by-claim construction analysis grounded in the text provided, and a practical “US landscape” map focused on how this kind of claim typically interacts with US competitor estates (complement/C5a/C5aR inhibitors), with what typically drives validity and infringement outcomes for this claim style.

---

What is US Patent 10,487,098 claiming: a C5a-binding inhibition method built on Formula I Markush scope?

Direct answer: The patent claims a method of inhibiting C5a binding by administering a therapeutically effective amount of a specific Formula I compound (or its pharmaceutical composition/salt), for treating a long, non-exclusive list of human diseases spanning inflammation, autoimmunity, oncology, cardiovascular and cerebrovascular indications.

How the independent claim is legally structured

Claim 1 is drafted as a classic “compound-defined method-of-use” claim:

1. Target/functional limitation: “inhibiting C5a binding in a human”
2. Patient condition framing: “suffering from or susceptible to a disease… treatable by such inhibition”
3. Broad indication list: inflammatory, autoimmune, oncologic, cardiovascular, cerebrovascular disorders
4. Administration limitation: administer a therapeutically effective amount of:
   • Formula I compound, or
   • pharmaceutical composition comprising the compound of Formula I (or acceptable salts)

Then the claim anchors the legal coverage to the chemical scaffold through a long set of variable definitions for substituents.

Markush-style variables: where infringement will hinge

The independent claim includes dense definitions for:

• R.sup.1 (multiple allowed substituent classes, including phosphonate/phosphate-like groups and heterocyclic/alkylene-aryl-like linkers)
• R.sup.2 (either H or various linker-connected functional moieties, including phosphonate/phosphate-like groups and heteroatom-containing linkers)
• R.sup.3 (H or a linker group containing phosphate-like substituent)
• Multiple sub-linker definitions:
  • A.sup.1 / A.sup.2 as aryl/cycloalkyl/heteroaryl/heterocyclyl (each optionally substituted)
  • L.sup.2, L.sup.3, L.sup.4, L.sup.5 as bonds or heteroatom-containing chain fragments
  • X.sup.1, X.sup.2 as terminal heteroatom/phosphate/carboxylic acid-like functional groups
• Optional substituent counts and identities (halogen, alkyl, haloalkyl, heteroalkyl, CN, NR.sup.yR.sup.z, SR.sup.y, OR.sup.y)

The key infringement issue is binary: an accused compound either fits within the literal variable constraints for Formula I (including what “optionally substituted with 1 to 6 R.sup.c groups” means in practice) or it does not. Because the claim is not written around an “equivalent” scaffold definition, small differences in the allowed heteroatoms, linker length ranges (C1-6, C4-7 etc.), or where the phosphorous/acid functionalities sit on the scaffold can be dispositive.

Disease list breadth: legal coverage vs. enforceability

Claim 1 uses a long disease taxonomy. Dependent claims 2-4 further enumerate explicit diseases, including:

• complement-related renal entities (aHUS, C3-glomerulopathies, dense deposit disease, MPGN, etc.)
• systemic autoimmune and inflammatory disorders (RA, SLE, vasculitis, IBD, psoriasis, etc.)
• ocular vascular disease (polypoidal choroidal vasculopathy, dry/wet AMD)
• neurologic and vascular events (Alzheimer’s disease, multiple sclerosis, stroke)
• cardiopulmonary and critical care conditions (ARDS, sepsis, septic shock, lung injury)
• transplant rejection and graft-versus-host disease
• a large oncology list (claim 4) covering diverse tumors

This kind of disease-list drafting is designed to block “non-core indication” defenses by ensuring the asserted disease is already recited. But it can also create:

• obviousness vulnerabilities if a single complement/C5a mechanism is used to claim disparate disease categories without a specific tying rationale
• written description and enablement pressure if the chemical scope is very broad and the mechanisms/disease mapping is not narrowly described in the specification (the claim text alone does not show that pressure, but the breadth invites it)

Functional limitation “inhibiting C5a binding”: scope implications

“Inhibiting C5a binding” is a functional target limitation. In infringement, the question becomes whether the accused compound:

• binds/blocks/antagonizes C5a binding to its binding partner (most commonly C5aR/C5a receptor or relevant binding interface), or
• otherwise prevents formation of a C5a binding complex in a way that matches the patent’s functional language.

If an accused product instead targets C5/C5a processing, C5 convertase indirectly, or blocks downstream signaling without affecting “binding” as construed, the literal functional limitation can become a fight over claim construction and evidence.

---

What diseases are explicitly covered in claims 2-4 and how do they map to C5a biology risk?

Direct answer: Claims 2-4 list dozens of disorders across renal complement disorders, autoimmune and inflammatory diseases, ocular vascular diseases, CNS/neurologic conditions, critical care inflammation, transplant rejection, and an extensive oncology set.

Renal complement and microangiopathy coverage (claims 2-3)

Included examples:

• atypical hemolytic uremic syndrome (aHUS)
• Hemolytic uremic syndrome
• C3-glomerulopathy, C3-glomerulonephritis
• dense deposit disease
• membranoproliferative glomerulonephritis (MPGN)
• “Membranoproliferative and glomerulonephritis” (claim 3)
• lupus nephritis/glomerulonephritis and related glomerular entities

Strategic implication: this aligns with the clinical use pattern of C5a-pathway therapeutics where complement-driven inflammation and neutrophil recruitment drive microvascular injury. For licensing and litigation, these are “high-value indication” categories where competitor patent estates often cluster around complement inhibition.

Autoimmune and inflammatory coverage (claims 2-3)

Examples include:

• Wegener’s granulomatosis (GPA)
• microscopic polyangiitis
• systemic lupus erythematosus, vasculitis, ANCA vasculitis
• rheumatoid arthritis
• inflammatory bowel disease, Crohn’s disease
• atopic dermatitis, chronic urticaria, psoriasis
• dermatomyositis, scleroderma, Guillain-Barre syndrome, myasthenia gravis
• uveitis

Strategic implication: the disease list is so broad that it can reduce “indication mismatch” defenses. The tradeoff is validity risk if the claim is treated as a mechanism-based invention without adequate disease-specific support.

Cardiovascular/cerebrovascular coverage embedded in claim 1 + explicit inclusions (claim 2)

Claim 1 includes cardiovascular and cerebrovascular. Claim 2 includes:

• stroke
• ischemia-reperfusion injury
• myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion
• atherosclerosis

Strategic implication: complement (including C5a) has known roles in vascular inflammation. However, the breadth of indication list makes the patent a “general complement inflammation” claim in practice, which can collide with broader complement pathway prior art.

Oncology coverage (claim 4)

Claim 4 enumerates diverse cancers including melanoma, lung cancer, lymphoma, sarcoma, carcinomas, and multiple rare tumor types.

Strategic implication: generic oncology lists often raise written description/enablement and obviousness issues if not tied to specific C5a-driven mechanisms in the specification. The claim still can be valuable if the asserted compound has demonstrated anti-tumor effects via C5a-mediated immune modulation, but the claim language alone does not show that tie.

---

What formulations are protected: what does “Formula I” composition coverage add beyond the method claim?

Direct answer: The independent claim covers both (i) administration of the Formula I compound and (ii) “a pharmaceutical composition comprising” the Formula I compound (or salt). That means formulation, excipient, and delivery form are not explicitly limited in claim text, but composition inclusion typically extends protection to product forms that contain the compound within the defined chemical scope.

Composition vs. method: where disputes usually start

Because the claim text does not specify dosage form (tablet, injection, inhalation) or excipient constraints, the scope likely includes any dosage form that contains Formula I (or the pharmaceutically acceptable salt). In litigation, disputes typically focus on:

• whether the marketed product contains the claimed Formula I species or only a close analog
• whether the product is a salt of the claimed compound within the claim’s “pharmaceutically acceptable salt” meaning
• whether a combination product is still “a pharmaceutical composition comprising” the Formula I compound

---

How does claim 5 expand scope using combination therapy with a large agent list?

Direct answer: Claim 5 adds administration of Formula I (or composition) together with one or more additional therapeutic agents, without limiting dosing sequencing or mechanistic relationship to C5a binding beyond that the combination is administered.

Claim 6 adds a long “additional therapeutic agents” list

Claim 6 specifies a large list of agent classes and named drugs, including:

• corticosteroids (prednisone, dexamethasone, hydrocortisone, etc.)
• immunosuppressants and biologics (obinutuzumab, rituximab, ocrelizumab, basiliximab, tocilizumab, clazakizumab, mepolizumab, infliximab, etc.)
• targeted small molecules (ibrutinib, nilotinib, imatinib, tofacitinib, everolimus, sirolimus, panobinostat, etc.)
• other immunomodulators and supportive agents

Strategic implication: this is drafted to foreclose generic “we are not in the same regimen” defenses. But the broad combination list can also become a validity target if the underlying invention is treated as an aggregation of known therapies plus a known target mechanism.

---

How strong is the patent estate for C5a-binding inhibition claims like this in the US?

Direct answer: Based on the claim style provided, US 10,487,098’s strength is greatest when the accused product is (i) within the literal Formula I definition and (ii) marketed or used for an included disease with (iii) evidence that it inhibits “C5a binding” as construed.

It is weakest where:

• the accused compound differs by one or more substituent/linker parameters outside the Markush range;
• the accused mechanism does not meet “binding inhibition” (e.g., affects complement cleavage indirectly or blocks receptor signaling without binding);
• enforcement depends on broad disease coverage where prosecution history or specification support is not tied to all recited diseases.

---

What generic entry risks exist for products using C5a inhibition, given this claim text?

Direct answer: Risks arise mainly from “compound-literal” infringement rather than generics-as-a-class. A generic would avoid infringement only if it does not include the claimed Formula I compound (including salts) or if it does not inhibit C5a binding in the claimed way.

If an ANDA/505(b)(2) pathway is pursued for a C5a-binding inhibitor:

• ANDA would be relevant if the product is a small-molecule identical compound/salt and is not protected by non-patent exclusivities or other blocking patents.
• 505(b)(2) is typical for new formulation/changes. A “composition” claim like this often blocks formulation-only carveouts unless the formulation is the same compound.

Key risk driver: because the claim is not limited to a particular route, dosage form, or regimen, a generic that matches the Formula I scaffold and delivers it systemically would have a direct pathway to literal coverage.

---

What patents are likely to be adjacent in the US landscape (mechanism and scaffold layers)?

Direct answer: In the US, C5a-pathway assets typically cluster into three patent layers that create a dense infringement map:

1. Target/biologic pathway patents (C5aR antagonists, C5a-neutralizing antibodies, C5 cleavage inhibitors, C5a binding constructs)
2. Small-molecule scaffold patents (analog series with Markush scope)
3. Method-of-use patents (therapeutic indications, combination regimens, patient subsets)

For US 10,487,098 specifically, the claim text indicates the primary novelty is embedded in the Formula I chemical scaffold and its use for a wide range of diseases.

How this affects “landscape” decisions: even if a competitor clears “target mechanism” constraints, the scaffold claims can still block. Even if scaffold coverage is escaped, method-of-use and combination claims can still block if they are present as separate assets.

---

What claim elements will most influence litigation outcomes under US claim construction?

Direct answer: The most litigated claim construction points for this claim style are:

• interpretation of Formula I Markush variables (especially linker lengths, optional substituent counts, and where phosphate/phosphonate-like groups appear)
• scope of “pharmaceutically acceptable salt”
• the meaning of “inhibiting C5a binding” (binding interface and whether functional inhibition suffices)
• whether combination therapy constitutes infringement when only one active is the claimed Formula I compound

Claim construction pressure points

• Markush boundaries: a single substituent outside allowed sets can avoid infringement.
• “Two of R1, R2, R3 are H, and one is other than H”: this creates a structural restriction that can exclude compounds where more than one position is substituted.
• Optional substitution limits (e.g., 1 to 6 R.sup.c groups): enforcement often turns on whether a particular analog meets substitution count.

---

Key Takeaways

• US Patent 10,487,098 is a broad method-of-use claim anchored to a specific “Formula I” chemical scaffold and a functional target limitation of inhibiting C5a binding.
• The disease coverage is expansive across renal complement disorders, autoimmune/inflammatory diseases, transplant settings, critical care inflammation, cardiovascular/cerebrovascular events, and a wide oncology list.
• Claims 5-6 materially expand regimen coverage by explicitly allowing combination therapy with a large catalog of immunomodulators, biologics, targeted agents, and steroids.
• Litigation and enforcement will likely hinge on literal inclusion within the Formula I Markush constraints, the “two of R1-R3 are H” structural condition, and claim construction of “inhibiting C5a binding.”
• Generic or biosimilar-style entry risk is primarily scaffold-driven: if the product does not contain the claimed Formula I species (or its salts), the risk drops sharply.

---

FAQs

1) Does US 10,487,098 cover all C5a pathway inhibitors or only those that inhibit C5a binding?

The claim is limited to inhibiting C5a binding and administering Formula I (or its composition/salts). Not all C5 pathway modulators automatically satisfy the binding inhibition limitation.

2) Can a product avoid infringement by changing dosage form or route of administration?

The claim text does not restrict route or dosage form, so avoidance would need to focus on scaffold inclusion/exclusion or on the functional “C5a binding inhibition” limitation.

3) How does the “two of R1, R2, R3 are H” requirement narrow coverage?

It constrains the chemical scope so that only one of those positions can carry a non-H substituent. Compounds with substitution at more than one of these positions would fall outside literal scope.

4) Does the large disease list mean the patent is easier to enforce for any indication?

It reduces indication mismatch defenses, but enforceability still depends on literal claim scope (Formula I plus C5a binding inhibition) and on validity against prior art and written description/enablement challenges.

5) How does claim 6 affect combination-therapy infringement?

It broadens regimen coverage to include administration with many named agents, making it harder to argue non-infringement on the basis that the claimed compound was used alongside other standard-of-care drugs.

---

References

No external sources were provided in the prompt beyond the claim text of US Patent 10,487,098; therefore no additional citable materials are included.

Details for Patent 10,487,098

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Iovance Biotherapeutics Manufacturing Llc	PROLEUKIN	aldesleukin	For Injection	103293	May 05, 1992		2039-03-19
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997		2039-03-19
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	December 10, 1997		2039-03-19
Novartis Pharmaceuticals Corporation	SIMULECT	basiliximab	For Injection	103764	May 12, 1998		2039-03-19